FMP

FMP

Enter

LZAGF - Lonza Group AG

photo-url-https://images.financialmodelingprep.com/symbol/LZAGF.png

Lonza Group AG

LZAGF

PNK

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

711.25 USD

-8.621 (-1.21%)

Historical Prices

From:

To:

page loading card

About

ceo

Dr. Wolfgang Wienand Ph.D.

sector

Healthcare

industry

Medical - Diagnostics & Research

exchange

PNK

Description

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small mo...

CIK

N/A

ISIN

CH0013841017

CUSIP

N/A

Address

Muenchensteinerstrasse 38

Phone

41 61 316 81 11

Country

CH

Employee

17,995

IPO Date

Feb 13, 2009

Financial Statement

01B2B3B4B2022 Q22022 Q42023 Q22023 Q42024 Q2RevenueNet Income

Earnings

0102030402021 Q22021 Q42022 Q22022 Q42023 Q22023 Q42024 Q22024 Q4EPS Consensus

LZAGF Financial Summary

CIK

-

Exchange

PNK

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

-

ISIN

CH0013841017

Country

CH

Price

711.25

Beta

0.86

Volume Avg.

144

Market Cap

50.02B

Shares

-

52-Week

498.98-747.75

DCF

-179.54

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

65.73

P/B

-

Website

https://www.lonza.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest LZAGF News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep